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In this issue of Cell Stem Stell, Bleau et al. report that activity of the drug transporter ABCG2 defines a tumor-
igenic stem-like side population (SP) isolated from glioma. Surprisingly, temozolomide, the first-line chemo-
therapeutic used for treatment of glioma, increased this side population, and even more so when PTEN was
deleted.Glioblastoma multiforme (GBM), the most
common form of primary brain tumor, is
characterized by an intrinsic heteroge-
neity among cell types comprising the
tumor mass, hence the name ‘‘multi-
forme.’’ The heterogeneity of cancer cell
populations and how to target them ther-
apeutically is a subject of great interest,
and many recent studies converge to
ask what role, if any, cancer stem cells
(CSCs) play in cancer pathogenesis.
CSCs appear to be resistant to chemo-
therapy, suggesting that these cells
persist after treatment and drive recur-
rence (Reya et al., 2001). In this issue of
Cell Stem Cell, Craig Jordan discusses
the possibility that CSCs, defined as
cancer cells that undergo self-renewal
and are capable of recapitulating the
entire tumor population, may not adhere
to the lineage diagrams and stable pheno-
types associated with ‘‘normal’’ stem
cells, and might therefore be more effec-
tively studied and targeted on the basis
of their known functional properties
(Jordan, 2009).
Indeed, Holland and coworkers used
just such a functional approach in their
study. It is known that efflux of specific
drugs by the membrane pump ABCG2
underlies chemotherapeutic resistance,
and also that stem cells can be flow
sorted as a side population (SP) because
they use the same mechanism to efflux
the DNA binding dye Hoechst 33342. It
has also been demonstrated that the SP
from glioma cell lines is enriched in tumor-
igenic cells with stem cell properties
(Patrawala et al., 2005). In their study,
Bleau et al. isolated SPs from PDGF-induced murine gliomas (Shih et al.,
2004) and human GBM samples and
characterized the tumorigenic properties
and drug sensitivity of these populations.
In normal mouse brain, the SP was visual-
ized as a discrete fraction and was found
to consist mainly of endothelial cells that
very actively excluded Hoechst 33342. In
contrast, the SP examined in tumor
samples expressed both endothelial and
stem cell markers and contained cells
that excluded dye over a significantly
broader activity range. Notably, the endo-
thelial cells in the tumor SPs exhibit
reduced ABCG2 activity, a finding raising
unanswered questions as to how reduced
ABCG2 transporter function might
contribute to the blood-brain barrier
disruption observed as a typical feature
of high-grade gliomas. The tumor-associ-
ated SP cells formed primary spheres
in neurosphere medium. SP numbers,
phenotype, and sphere formation ability
were found to be increased in secondary
spheres, suggesting that ABCG2 activity
contributes to the selection and enrich-
ment of SP cells.
Bleau et al. next cultured the SP cells
in neurosphere medium and examined
how the SP phenotype was altered by
phosphoinositide-30 kinase (PI3K)/Akt
signaling and PTEN deletion. The PI3K/
Akt pathway is activated, and PTEN, a
negative regulator of PI3K signaling, is
mutated or deleted in the majority of
GBM patients (Mclendon, 2008; Parsons
et al., 2008). Loss of PTEN in conjunction
with loss of p53 maintains both NSCs and
glioma CSCs in an undifferentiated state,
promoting self-renewal and inhibitingCell Stem Cedifferentiation, an effect attributed in part
to activation of myc (Zheng et al., 2008).
The authors found that PTEN deletion
doubled the number of SP cells present
in tumor-derived spheres, while PI3K inhi-
bition led to loss of ABCG2 pump expres-
sion at the plasma membrane and
a subsequent reduction of the SP frac-
tions in both PTEN and wild-type cells.
Collectively, these results suggest that
PTEN-induced ABCG2 activity is respon-
sible for the SP phenotype in glioma
CSCs, extending and confirming previous
results in other cell types (Takada et al.,
2005; Zhou et al., 2007).
Most notably, from a clinical perspec-
tive, Bleau et al. found that treating the
SP spheres with the GBM chemothera-
peutic temozolomide increased the SP
fraction, and even more so in PTEN null
spheres. These results led the authors to
hypothesize that PTEN loss leads to
increased temozolomide resistance. Te-
mozolomide treatment also shortened
tumor latency; mice grafted with tumor-
derived SP spheres cultured with temozo-
lomide started to develop tumors after
25 days, while untreated transplants
grew tumors after 40 days. Interestingly,
temozolomide itself was not a substrate
for ABCG2. The apparent increase in SP
was instead traced to elevated activity of
O6-methyl-guanine-DNA methyltransfer-
ase, a DNA repair enzyme known to
mediate temozolomide resistance. To
demonstrate relevance to human GBM,
Bleau et al. next showed that blockade of
either PI3K or Akt also downregulated the
SP phenotype in primary patient-derived
GBM SP spheres. Orthotopic xenograftingll 4, March 6, 2009 ª2009 Elsevier Inc. 191
Cell Stem Cell
Previewsof SP cells from human GBM led to
shortened latency for tumor forma-
tion compared to the main popula-
tion, consistent with SP cells being
enriched for CSCs also in human
tumors.
Taken together, these findings
offer important scientific insight,
and yet seem paradoxical with
respect to their therapeutic impli-
cations. Bleau et al. (2009) showed
that the abundance of the stem-
like glioma cells was readily modi-
fied through either acquisition of
mutation (loss of PTEN) or in
response to treatment with temo-
zolomide (Figure 1). Importantly,
while temozolomide, the most
effective chemotherapy used for
GBM, essentially sets the stage
for recurrent drug-resistant di-
sease, Bleau et al. also demon-
strate that inhibitors of PI3K, now
in clinical trials in cancer, may be
useful in blocking temozolomide-
driven expansion of the SP. These find-
ings also show that the relative abun-
dance and drug resistance of CSCs
can change during malignant pro-
gression and in response to therapy.
Thus acquisition of stemness in cancer
is perhaps more likely a continually
turning ‘‘dial’’ rather than an on/off
‘‘switch.’’ Clearly, future studies are
needed to understand why both loss of
PTEN and temozolomide expand the SP,
and how to translate these findings into
improved therapeutic approaches for
this deadly tumor.
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Figure 1. Models to Describe How Loss of PTEN and
Treatment with Temozolomide May Lead to
Chemoresistance in Glioma
(A) Loss of PTEN leads to increased ABCG2 activity (represented
by black squares) in a subset of cells, resulting in increased self-
renewal and net chemoresistance.
(B) The alkylating agent temozolomide most effectively targets
non-SP cells, leading to relative expansion of a chemoresistant
(ABCG2-positive) SP fraction.LOCKing in Cellular Potential
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Recently in Nature Genetics, Wen et al. (2009) report that H3K9me2 modification is more abundant in differ-
entiated cells than in embryonic stem cells and that it decorates chromatin in repressive blocks.
A spectrum of differentiated cell types that
constitute higher organisms arise from
pluripotent cells that are found in the inner
cell mass of blastocyst-stage embryos.
Cellular potential is gradually lost as cells
acquire specific fates during development
(Figure 1A), although under certain exper-
imental conditions, their potential can be
reset (via reprogramming, Figure 1A).
The exchange of cellular potential for func-
tional specialization takes place—in
almost all cases—without loss of genetic
material, a result that has led to specula-
tions that progressive silencing of the
genome could underwrite directional
differentiation (Spemann, 1938). Epige-
netic mechanisms capable of modulating
the accessibility of the genome to DNA-
binding transcription factors have been
implicated in this process (Reik, 2007),
particularly dynamic changes in DNA
methylation and covalent modification to
histone tails. The importance of these
epigenetic mechanisms for normal devel-
opment is underscored by the prevalence
of lethality among embryos lacking DNA
and histone methyltransferases.
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